knownwell Reports Superior, Durable Obesity Outcomes in First Clinical Results Dataset

New updates have been reported about knownwell.

knownwell has released its first Clinical Outcomes Report, presenting real-world data from 1,807 patients treated between February 2023 and February 2025 that positions its hybrid obesity-care model as a differentiated asset versus GLP-1–only approaches. Patients across multiple states, obesity classes, and care modalities achieved an average 15.9% weight loss, with 88% losing at least 5% of body weight and 74% losing at least 10%, while 97% maintained their weight loss over 12 months with no more than 5% regain, a durability rate reported as nearly five times national averages.

Critically for payors and health systems evaluating return on investment from anti-obesity medications, knownwell reports 50% lower lean mass loss than published GLP-1 clinical trial benchmarks based on SECA body composition measurements, suggesting potential for better long-term metabolic and functional outcomes. The company attributes these results to its multidisciplinary, physician-led model that integrates obesity medicine, primary care, nutrition, pharmacy, and health coaching across virtual, hybrid, and in-person settings, which Chief Medical Officer and Co-Founder Dr. Angela Fitch says is designed to move beyond prescription-only telehealth models by providing longitudinal, comprehensive care that can reduce discontinuation, improve adherence, and enhance the economic value of obesity pharmacotherapy for stakeholders.